KDR and neoplasm: Sorafenib is the first oral multi‐kinase inhibitor that targets VEGFR‐1, VEGFR‐2 and VEGFR‐3 to inhibit angiogenesis, the RET gene also known as RET/PTC rearrangement, RAF (including BRAFV600E) and platelet‐derived growth factor receptors to inhibit tumour progression.47